<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003364</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-SCI-01</org_study_id>
    <nct_id>NCT03003364</nct_id>
  </id_info>
  <brief_title>Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury</brief_title>
  <official_title>A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Neurorehabilitació Institut Guttmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Recerca Clínica S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syntax for Science, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo&#xD;
      controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age&#xD;
      affected with chronic traumatic spinal cord will enter the study with the objective to assess&#xD;
      the safety and to obtain efficacy data in intrathecal administration of expanded Wharton's&#xD;
      jelly mesenchymal stem cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo&#xD;
      controlled, clinical trial in which 10 patients from 18 to 65 years of age affected with&#xD;
      chronic traumatic spinal cord will enter the study with the objective to assess the safety&#xD;
      and to obtain efficacy data in intrathecal administration (L3 level) of expanded Wharton's&#xD;
      jelly mesenchymal stem cells. Following the administration patients will remain for 24 h at&#xD;
      the hospital and thereafter will be discharged. For the first period, the follow-up is&#xD;
      planned at day 7 and at 1, 3 and 6 months. At month 6, the patients will be treated in a&#xD;
      crossover way (second period) and will follow the same schedule for the follow-up. First&#xD;
      clinical trial evaluation will be performed at 12 month follow-up. From 12 to 18 month after&#xD;
      the first infusion, patients will be randomized again to active treatment or placebo&#xD;
      (double-blind) in order to assess the safety and efficacy of a second dose at 12 month&#xD;
      follow-up. Thereafter, patients will be followed up at 24 and 36 months as part of a&#xD;
      long-term follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Actual">February 11, 2020</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent and severity of a patient's spinal cord injury</measure>
    <time_frame>6 months</time_frame>
    <description>ASIA Impairment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor electrophysiology assessment</measure>
    <time_frame>6 month</time_frame>
    <description>Evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatosensory electrophysiology assessment</measure>
    <time_frame>6 month</time_frame>
    <description>Evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical nerve stimulation on pain perception</measure>
    <time_frame>6 month</time_frame>
    <description>Pain threshold perception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mictional dysfunction</measure>
    <time_frame>6 month</time_frame>
    <description>Urodynamic testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal sphincter integrity</measure>
    <time_frame>6 month</time_frame>
    <description>Anorectal manometry test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain</measure>
    <time_frame>6 months</time_frame>
    <description>Numerical scale (0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity</measure>
    <time_frame>6 months</time_frame>
    <description>Modified Ashworth scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality</measure>
    <time_frame>6 months</time_frame>
    <description>SCIM III scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)</measure>
    <time_frame>6 months</time_frame>
    <description>WHOQOL BREF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary disorder</measure>
    <time_frame>6 months</time_frame>
    <description>Qualiveen questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size injury</measure>
    <time_frame>12 months</time_frame>
    <description>Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of allogeneic cells</measure>
    <time_frame>1 month</time_frame>
    <description>Chimerism in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology</measure>
    <time_frame>1 months</time_frame>
    <description>Antibodies anti-HLA in peripherical blood and in cerebrospinal fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Spinal Cord Injury, Chronic</condition>
  <arm_group>
    <arm_group_label>XCEL-UMC-BETA/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/XCEL-UMC-BETA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-UMC-BETA</intervention_name>
    <description>Intrathecal allogeneic cell therapy in a blinded syringe</description>
    <arm_group_label>Placebo/XCEL-UMC-BETA</arm_group_label>
    <arm_group_label>XCEL-UMC-BETA/placebo</arm_group_label>
    <other_name>Expanded MSC from Wharton Jelly</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in a blinded syringe</description>
    <arm_group_label>Placebo/XCEL-UMC-BETA</arm_group_label>
    <arm_group_label>XCEL-UMC-BETA/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Single spinal cord injury lesion caused by trauma&#xD;
&#xD;
          2. Affected cord segments between T2 and T11, confirmed by magnetic resonance&#xD;
&#xD;
          3. Complete paraplegia (ASIA A)&#xD;
&#xD;
          4. Chronic disease state (between 12 months and 5 years after the injury)&#xD;
&#xD;
          5. Patients from 18 to 65 years of age, both sexes&#xD;
&#xD;
          6. Life expectancy &gt; 2 years&#xD;
&#xD;
          7. Confidence that the patient will attend the follow-up visits.&#xD;
&#xD;
          8. Given informed consent in writing&#xD;
&#xD;
          9. Patient is able to understand the study and its procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mechanic ventilation&#xD;
&#xD;
          2. Lesion affecting multiple levels&#xD;
&#xD;
          3. Lesion length superior to 3 spinal cord segments, assessed by magnetic resonance&#xD;
&#xD;
          4. Penetrating trauma affecting the spinal cord&#xD;
&#xD;
          5. Positive serology to HIV, HBV, HCV and or syphilis&#xD;
&#xD;
          6. Pregnant woman or without proper anticonceptive measures according to the&#xD;
             investigator, or breath feeding&#xD;
&#xD;
          7. Use of metal implants that complicates the MRI interpretation&#xD;
&#xD;
          8. Planned spinal surgery within subsequent 24 month after entering the trial&#xD;
&#xD;
          9. Intrathecal medication or immunosuppressive drugs the previous 60 days.&#xD;
&#xD;
         10. Neurodegenerative diseases&#xD;
&#xD;
         11. Significant abnormal laboratory tests that contraindicates patient's participation in&#xD;
             the study.&#xD;
&#xD;
         12. Neoplasia within the previous 5 years, or without complete remission&#xD;
&#xD;
         13. Patient with difficulty for communicating&#xD;
&#xD;
         14. Participation in another clinical trial or treated with an investigational medicinal&#xD;
             product the previous 60 days&#xD;
&#xD;
         15. Contraindication for lumbar punction&#xD;
&#xD;
         16. Other pathologic conditions or circumstances that could complicate the participation&#xD;
             of the patient in the study according to medical criteria&#xD;
&#xD;
         17. The patient does not accept to be followed-up for a period that could exceed the&#xD;
             clinical trial length&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Vidal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Neurorehabilitació Institut Guttmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Neurorehabilitació Institut Guttmann</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://bancsang.net/en_index/</url>
    <description>Blood and Tissue Bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.guttmann.com/en</url>
    <description>Hospital de Neurorehabilitació Institut Guttmann</description>
  </link>
  <link>
    <url>http://www.ccma.cat/tv3/marato/en/</url>
    <description>Marató TV3</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

